In vitro bromodeoxyuridine labeling of malignant neoplasms: A comparative study with flow cytometry cell-cycle analysis Journal Article


Authors: Lloveras, B.; Garin-Chesa, P.; Myc, A.; Melamed, M.
Article Title: In vitro bromodeoxyuridine labeling of malignant neoplasms: A comparative study with flow cytometry cell-cycle analysis
Abstract: Proliferative fraction has been defined as as independent prognostic marker for some malignant neoplasms. An estimate of the proliferative fraction can be obtained by cell-cycle analysis of flow cytometric DNA measurements. However, overlapping DNA distributions of aneuploid neoplasms are difficult to analyze, even with sophisticated computer programs, and results are not always reproducible. Bromodeoxyuridine (BrdUrd) labeling followed by immunohistochemical detection has been proposed as an alternative, simple, and accurate method for identifying and counting DNA synthesizing cells. In vitro BrdUrd labeling was performed on 87 tumors, including 35 lung cancers, 25 breast carcinomas, and 27 tumors of other origin. Results were compared with flow cytometric S-phase estimates in 46 cases. Mean BrdUrd labeling of lung tumors was 8.5% +/- 5.2%, compared with a mean flow cytometric S-phase fraction of 20% +/- 18.4%. Mean BrdUrd labeling of breast carcinomas was 6.8% +/- 3.8%, compared with a mean flow cytometric S-phase fraction of 12.5% +/- 9.9%. In both tumor types, BrdUrd labeling correlated well with histologic grade. Correlation between BrdUrd labeling and flow cytometric S-phase estimates were generally poor, particularly with aneuploid tumors.
Keywords: flow cytometry; adenocarcinoma; tumors; prognostic factors; tumor growth; breast-cancer; carcinomas; index; invivo; cellular proliferation; invitro; s-phase fraction; tumor grading
Journal Title: American Journal of Clinical Pathology
Volume: 101
Issue: 6
ISSN: 0002-9173
Publisher: Oxford University Press  
Date Published: 1994-06-01
Start Page: 703
End Page: 707
Language: English
ACCESSION: WOS:A1994NQ30200007
DOI: 10.1093/ajcp/101.6.703
PROVIDER: wos
PUBMED: 8209855
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors